Logo
Login
$FDMT
$11.03 +$0.23 (2.13%) Close

Company Executives

$FDMT Management Team

Dr. Dhaval Desai

Chief Development Officer

Age -
Compensation -
Sex Male

Mr. Christopher Simms

Chief Commercial Officer

Age 49
Compensation -
Sex Male

Mr. Julian Pei

Head of Investor Relations and Corporate Finance

Age -
Compensation -
Sex Male

Dr. John Milligan

Executive Chairman of the Board

Age 64
Compensation $646.8K USD
Sex Male

Dr. David Kirn

President

Chief Executive Officer

Co-Founder

Director

Age 63
Compensation $1.009M USD
Sex Male

Dr. Robert Kim

Chief Medical Officer

Age 64
Compensation $3.965M USD
Sex Male

Dr. Scott Bizily

Chief Legal Officer and Corporate Secretary

Age 53
Compensation -
Sex Male

Mr. Kristian Humer

Chief Financial Officer and Principal Financial Officer

Age 50
Compensation -
Sex Male

Board of Directors

From the proxy statement filed Apr 28, 2026
Directors
8
serving now
Independent
3 of 4
stated in the proxy; 4 not stated
Average tenure
6.9 years
from year joined
CEO also chairs the board
No
John F. Milligan, Ph.D.
Director Age On board Independent Committees Other public boards 2025 pay Source
David Kirn, M.D.
CEO
 64 2013
13 years
 Not independent None stated None stated Paid as CEO
Glenn Sblendorio
70 2026
0 years
 Not stated
Compensation Committee
Mineralys Therapeutics, Inc., Amicus Therapeutics, Inc. Not stated
Jacob Chacko, M.D., MBA
47 2019
7 years
 Independent None stated None stated $135,000
Susannah Gray, MBA
65 2020
6 years
 Independent None stated AnaptysBio, Inc. $135,000
Charles Theuer, M.D., Ph.D.
62 2015
11 years
 Independent None stated None stated $135,000
Nancy Miller-Rich
67 2020
6 years
 Not stated
Compensation Committee
Aldeyra Therapeutics, Inc. $122,500
John F. Milligan, Ph.D.
Board chair
 65 2020
6 years
 Not stated None stated Pacific Biosciences of California $255,000
Shawn Cline Tomasello, MBA
67 2020
6 years
 Not stated None stated Cabaletta Bio, Inc. $132,500

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 28, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans